1. Ansari, D, Tingstedt, B, Andersson, B, et al. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016;12(16):1929-1946. doi:10.2217/fon-2016-0010.
Google Scholar | Crossref | Medline2. Goral, V . Pancreatic cancer: pathogenesis and diagnosis. Asian Pac J Cancer Prev APJCP. 2015;16(14):5619-5624. doi:10.7314/apjcp.2015.16.14.5619.
Google Scholar | Crossref | Medline3. Schizas, D, Charalampakis, N, Kole, C, et al. Immunotherapy for pancreatic cancer: a 2020 update. Canc Treat Rev. 2020;86:102016. doi:10.1016/j.ctrv.2020.102016
Google Scholar | Crossref | Medline4. Heinrich, S, Lang, H. Neoadjuvant therapy of pancreatic cancer: definitions and benefits. Int J Mol Sci. 2017;18(8):1622. doi:10.3390/ijms18081622
Google Scholar | Crossref5. Burris, HA, Moore, MJ, Andersen, J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-2413. doi:10.1200/JCO.1997.15.6.2403.
Google Scholar | Crossref | Medline | ISI6. Nawaz, J, Rasul, A, Shah, MA, et al. Cardamonin: a new player to fight cancer via multiple cancer signaling pathways. Life Sci. 2020;250:117591. doi:10.1016/j.lfs.2020.117591.
Google Scholar | Crossref | Medline7. Yue, Y, Liu, L, Liu, P, et al. Cardamonin as a potential treatment for melanoma induces human melanoma cell apoptosis. Oncology Letters. 2020;19(2):1393-1399. doi:10.3892/ol.2019.11242.
Google Scholar | Crossref | Medline8. Niu, P, Li, J, Chen, H, Zhu, Y, Zhou, J, Shi, D. Anti‑proliferative effect of cardamonin on mTOR inhibitor‑resistant cancer cells. Mol Med Rep. 2020;21(3):1399-1407. doi:10.3892/mmr.2019.10898
Google Scholar | Crossref | Medline9. Hossan, MS, Break, MKB, Bradshaw, TD, et al. Novel semi-synthetic Cu (II)-cardamonin complex exerts potent anticancer activity against triple-negative breast and pancreatic cancer cells via inhibition of the Akt signaling pathway. Molecules. 2021;26(8):2166. doi:10.3390/molecules26082166
Google Scholar | Crossref | Medline10. Du, J, Tang, B, Wang, J, et al. Antiproliferative effect of alpinetin in BxPC-3 pancreatic cancer cells. Int J Mol Med. 2012;29(4):607-612. doi:10.3892/ijmm.2012.884
Google Scholar | Crossref | Medline11. Burgering, BMT, Kops, GJPL. Cell cycle and death control: long live forkheads. Trends Biochem Sci. 2002;27(7):352-360. doi:10.1016/s0968-0004(02)02113-8.
Google Scholar | Crossref | Medline12. McGovern, UB, Francis, RE, Peck, B, et al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Canc Therapeut. 2009;8(3):582-591. doi:10.1158/1535-7163.MCT-08-0805.
Google Scholar | Crossref | Medline | ISI13. Savkovic, SD . Decreased FOXO3 within advanced human colon cancer: implications of tumour suppressor function. Br J Canc. 2013;109(2):297-298. doi:10.1038/bjc.2013.354.
Google Scholar | Crossref | Medline14. Hu, JQ, Deng, F, Hu, XP, Zhang, W, Zeng, XC, Tian, XF. Histone deacetylase SIRT6 regulates chemosensitivity in liver cancer cells via modulation of FOXO3 activity. Oncol Rep. 2018;40(6):3635-3644. doi:10.3892/or.2018.6770
Google Scholar | Crossref | Medline15. Sun, S, Kim, MJ, Omar, AM, Duy Phan, N, Aoike, M, Awale, S. GDP induces PANC‐1 human pancreatic cancer cell death preferentially under nutrient starvation by inhibiting PI3K/Akt/mTOR/autophagy signaling pathway. Chem Biodivers. 2021;18(9):e2100389. doi:10.1002/cbdv.202100389. [Epub ahead of print]
Google Scholar | Crossref | Medline16. Zhou, X, Zhou, R, Li, Q, et al. Cardamonin inhibits the proliferation and metastasis of non-small-cell lung cancer cells by suppressing the PI3K/Akt/mTOR pathway. Anti Canc Drugs. 2019;30(3):241-250. doi:10.1097/CAD.0000000000000709
Google Scholar | Crossref | Medline17. Wang, Z, Liu, H, Hu, Q, et al. Cardamonin inhibits the progression of oesophageal cancer by inhibiting the PI3K/AKT signalling pathway. J Canc. 2021;12(12):3597-3610. doi:10.7150/jca.55519. PMID: 33995637
Google Scholar | Crossref | Medline18. Wang, Z, Tang, X, Wu, X, et al. Cardamonin exerts anti-gastric cancer activity via inhibiting LncRNA-PVT1-STAT3 axis. Biosci Rep. 2019;39(5):BSR20190357. doi:10.1042/BSR20190357
Google Scholar | Crossref | Medline19. Jin, J, Qiu, S, Wang, P, et al. Cardamonin inhibits breast cancer growth by repressing HIF-1α-dependent metabolic reprogramming. J Exp Clin Canc Res. 2019;38(1):377. doi:10.1186/s13046-019-1351-4
Google Scholar | Crossref | Medline20. Wang, Z, Ahmad, A, Li, Y, Banerjee, S, Kong, D, Sarkar, FH. Forkhead box M1 transcription factor: a novel target for cancer therapy. Canc Treat Rev. 2010;36(2):151-156. doi:10.1016/j.ctrv.2009.11.006.
Google Scholar | Crossref | Medline21. Kalin, TV, Ustiyan, V, Kalinichenko, VV. Multiple faces of FoxM1 transcription factor. Cell Cycle. 2011;10(3):396-405. doi:10.4161/cc.10.3.14709.
Google Scholar | Crossref | Medline22. Hu, G, Yan, Z, Zhang, C, et al. FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression [Published 2019 May 9]. J Exp Clin Canc Res. 2019;38(1):188. doi:10.1186/s13046-019-1202-3
Google Scholar | Crossref | Medline23. Varghese, V, Magnani, L, Harada-Shoji, N, et al. FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression [Published 2019 Feb 6]. Sci Rep. 2019;9(1):1505. doi:10.1038/s41598-018-38017-0
Google Scholar | Crossref | Medline24. Ilic, M, Ilic, I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694-9705. doi:10.3748/wjg.v22.i44.9694.
Google Scholar | Crossref | Medline25. Vincent, A, Herman, J, Schulick, R, Hruban, RH, Goggins, M. Pancreatic cancer. Lancet. 2011;378(9791):607-620. doi:10.1016/S0140-6736(10)62307-0.
Google Scholar | Crossref | Medline | ISI26. Grasso, C, Jansen, G, Giovannetti, E. Drug resistance in pancreatic cancer: impact of altered energy metabolism. Crit Rev Oncol Hematol. 2017;114:139-152. doi:10.1016/j.critrevonc.2017.03.026.
Google Scholar | Crossref | Medline27. Wang, ZH, Zhou, J, Shen, L. Zhonghua Zhongliu Zazhi. 2017;39(9):712-716. doi:10.3760/cma.j.issn.0253-3766.2017.09.014.
Google Scholar | Crossref | Medline28. Hwang, RF, Moore, T, Arumugam, T, Rivera, A, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Canc Res. 2008;68(3):918-926. doi:10.1158/0008-5472.CAN-07-5714.
Google Scholar | Crossref | Medline29. Wang, K, Lv, Q, Miao, Y-m, Qiao, S-m, Dai, Y, Wei, Z-f. Cardamonin, a natural flavone, alleviates inflammatory bowel disease by the inhibition of NLRP3 inflammasome activation via an AhR/Nrf2/NQO1 pathway. Biochem Pharmacol. 2018;155:494-509. doi:10.1016/j.bcp.2018.07.039.
Google Scholar | Crossref | Medline30. Niu, P, Li, J, Chen, H, Zhu, Y, Zhou, J, Shi, D. Anti-proliferative effect of cardamonin on mTOR inhibitor-resistant cancer cells. Mol Med Rep. 2020;21(3):1399-1407. doi:10.3892/mmr.2019.10898.
Google Scholar | Crossref | Medline31. James, S, Aparna, JS, Paul, AM, et al. Cardamonin inhibits colonic neoplasia through modulation of MicroRNA expression [Published 2017 Oct 24]. Sci Rep. 2017;7(1):13945. doi:10.1038/s41598-017-14253-8.
Google Scholar | Crossref | Medline32. Niu, P-G, Zhang, Y-X, Shi, D-H, Liu, Y, Chen, Y-Y, Deng, J. Cardamonin inhibits metastasis of lewis lung carcinoma cells by decreasing mTOR activity [Published 2015 May 21]. PloS One. 2015;10(5):e0127778. doi:10.1371/journal.pone.0127778.
Google Scholar | Crossref | Medline33. Li, S-J, Sun, S-J, Gao, J, Sun, F-B. Wogonin induces Beclin-1/PI3K and reactive oxygen species-mediated autophagy in human pancreatic cancer cells. Oncology Letters. 2016 Dec;12(6):5059-5067. doi:10.3892/ol.2016.5367.
Google Scholar | Crossref | Medline34. Ding, G, Xu, X, Li, D, et al. Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation. Cell Death Dis. 2020;11(10):893. doi: 10.1038/s41419-020-03019-2
Google Scholar | Crossref | Medline35. Guo, Y, Tong, Y, Zhu, H, et al. Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF-β/Smad signaling pathways. Cell Biol Toxicol. 2021;37(3):479-496. doi:10.1007/s10565-020-09562-0
Google Scholar | Crossref | Medline36. Zeng, S, Pöttler, M, Lan, B, Grützmann, R, Pilarsky, C, Yang, H. Chemoresistance in pancreatic cancer. Int J Mol Sci. 2019;20(18):4504. doi:10.3390/ijms20184504
Google Scholar | Crossref37. Arumugam, T, Ramachandran, V, Fournier, KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Canc Res. 2009;69(14):5820-5828. doi:10.1158/0008-5472.CAN-08-2819
Google Scholar | Crossref | Medline38. Long, J, Zhang, Y, Yu, X, et al. Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets. 2011;15(7):817-828. doi:10.1517/14728222.2011.566216
Google Scholar | Crossref | Medline39. Shi, W, Zhang, C, Ning, Z, et al. Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression [Published 2019 Feb 6]. J Exp Clin Canc Res. 2019;38(1):60. doi:10.1186/s13046-019-1055-9.
Google Scholar | Crossref | Medline40. Xian, G, Zhao, J, Qin, C, Zhang, Z, Lin, Y, Su, Z. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis. Canc Lett. 2017;385:65-74. doi:10.1016/j.canlet.2016.11.006.
Google Scholar | Crossref | Medline41. Alasiri, G, Jiramongkol, Y, Zona, S, et al. Regulation of PERK expression by FOXO3: a vulnerability of drug-resistant cancer cells. Oncogene. 2019;38(36):6382-6398. doi:10.1038/s41388-019-0890-7.
Google Scholar | Crossref | Medline42. Song, K-H, Woo, SR, Chung, J-Y, et al. REP1 inhibits FOXO3-mediated apoptosis to promote cancer cell survival [Published 2017 Jan 5]. Cell Death Dis. 2017;8(1):e2536. doi:10.1038/cddis.2016.462.
Google Scholar | Crossref | Medline43. Hu, JQ, Deng, F, Hu, XP, Zhang, W, Zeng, XC, Tian, XF. Histone deacetylase SIRT6 regulates chemosensitivity in liver cancer cells via modulation of FOXO3 activity. Oncol Rep. 2018;40(6):3635-3644. doi:10.3892/or.2018.6770.
Google Scholar | Crossref | Medline44. Ho, KK, Myatt, SS, Lam, EW-F. Many forks in the path: cycling with FoxO. Oncogene. 2008;27(16):2300-2311. doi:10.1038/onc.2008.23.
Google Scholar | Crossref | Medline